News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PerkinElmer, Inc. (PKI) and Verinata Health, Inc. Announce Collaboration to Expand Access to Non-Invasive Prenatal Test for Down Syndrome and Other Chromosomal Abnormalities


1/9/2013 9:42:51 AM

WALTHAM, Mass. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) and Verinata Health, Inc., today announced a strategic agreement for expanding access to Verinata’s verifi® test, the most comprehensive non-invasive prenatal test (NIPT) currently available for high-risk pregnancies. The verifi® test, which is performed at Verinata’s CLIA-certified, California laboratory, uses a single maternal blood draw as early as 10 weeks of pregnancy to detect multiple fetal chromosomal aneuploidies. Chromosomal aneuploidy is an abnormal number of chromosomes.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES